MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1164/rccm.202308-1326oc

Медицинская библиотека · American journal of respiratory and critical care medicine · 2024

The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Recipients with Chronic Rejection.

Combs Michael P, Luth Jenna E, Falkowski Nicole R, Wheeler David S, Walker Natalie M, Erb-Downward John R, Wakeam Elliot, Sjoding Michael W, Dunlap Daniel G, Admon Andrew J, Dickson Robert P, Lama Vibha N

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Rationale: Chronic lung allograft dysfunction (CLAD) is the leading cause of death after lung transplant, and azithromycin has variable efficacy in CLAD. The lung microbiome is a risk factor for developing CLAD, but the relationship between lung dysbiosis, pulmonary inflammation, and allograft dysfunction remains poorly understood. Whether lung microbiota predict outcomes or modify treatment response after CLAD is unknown.

Objectives

To determine whether lung microbiota predict post-CLAD outcomes and clinical response to azithromycin.

Methods

Retrospective cohort study using acellular BAL fluid prospectively collected from recipients of lung transplant within 90 days of CLAD onset. Lung microbiota were characterized using 16S rRNA gene sequencing and droplet digital PCR. In two additional cohorts, causal relationships of dysbiosis and inflammation were evaluated by comparing lung microbiota with CLAD-associated cytokines and measuring ex vivo P. aeruginosa growth in sterilized BAL fluid. Measurements and Main

Results

Patients with higher bacterial burden had shorter post-CLAD survival, independent of CLAD phenotype, azithromycin treatment, and relevant covariates. Azithromycin treatment improved survival in patients with high bacterial burden but had negligible impact on patients with low or moderate burden. Lung bacterial burden was positively associated with CLAD-associated cytokines, and ex vivo growth of P. aeruginosa was augmented in BAL fluid from transplant recipients with CLAD.

Conclusions

In recipients of lung transplants with chronic rejection, increased lung bacterial burden is an independent risk factor for mortality and predicts clinical response to azithromycin. Lung bacterial dysbiosis is associated with alveolar inflammation and may be promoted by underlying lung allograft dysfunction.

Для цитирования: Combs Michael P, Luth Jenna E, Falkowski Nicole R, Wheeler David S, Walker Natalie M, Erb-Downward John R, Wakeam Elliot, Sjoding Michael W, Dunlap Daniel G, Admon Andrew J, Dickson Robert P, Lama Vibha N. The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Recipients with Chronic Rejection.. American journal of respiratory and critical care medicine. 2024. DOI: 10.1164/rccm.202308-1326oc.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.